Brokerages are adopting a selective approach in the asset management sector while expressing caution towards certain pharmaceutical companies. Motilal Oswal has reaffirmed its 'buy' rating on UTI Asset Management Company (AMC) and Aditya Birla Sun Life AMC, attributing this to consistent trends in assets under management (AUM) and robust inflows from systematic investment plans (SIPs). These factors suggest improving long-term growth potential despite some short-term margin pressures. On the other hand, Goldman Sachs has taken a more conservative stance on Dr. Reddy's Laboratories, indicating a downgrade due to changing growth dynamics within the pharmaceutical industry. This mixed outlook reflects the evolving landscape of these sectors, with asset management showing resilience while pharmaceuticals face challenges.